β-glucans encapsulated in liposomes

• US 7,011,845 B2
• Filed: 05/09/2000
• Issued: 03/14/2006
• Est. Priority Date: 05/09/2000
• Status: Expired due to Fees

• Current Assignee: Ajinomoto Co., Inc., MCP Hahnemann University (Drexel University)
• Original Assignee: Ajinomoto Co., Inc., MCP Hahnemann University (Drexel University)
• Inventors: Kaneko, Yutaro, Kozbor, Danuta
• Primary Examiner(s): Kishore, Gollamudi S.
• Application Number:
  US09/566,993
• Publication Number:
  US 20020146448A1
• Time in Patent Office: 2,135 Days
• Field of Search: 620/652, 514/23, 514/25, 424/430, 424/433, 424/434, 424/435, 424/436, 424/450
• US Class Current: 424/450
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Liposomes encapsulating a β-glucan have an improved activity of enhancing a cellular immunity, especially when they are transmucosally administered. Thus, the liposomes are useful for the treatment or prevention of infection or tumor.

Claims

1. A method for treating HIV infection in a subject, comprising orally administering a beta-glucan encapsulated in a liposome to said subject in an amount effective to treat HIV infection, wherein the vesicles of said liposome have a multilamellar structure with distinct striated organization.

3. The method of claim 1 wherein the beta-glucan is lentinan or curdlan.

4. The method of claim 1, wherein the beta-glucan is lentinan.

5. The method of claim 1 wherein the beta-glucan is curdlan.

6. The method of claim 1 wherein the molecular weight of the beta-glucan is from 1,000 to 2,000,000.

7. The method of claim 1 wherein the molecular weight of the beta-glucan is from 5,000 to 1,500,000.

8. The method of claim 1 further comprising administering an HIV vaccine to said subject.

9. The method of claim 8, wherein said HIV vaccine is administered before the beta-glucan encapsulated in a liposome.

10. The method of claim 8, wherein said HIV vaccine is administered after the beta-glucan encapsulated in a liposome.

11. The method of claim 8, wherein said HIV vaccine and beta-glucan encapsulated in a liposome are administered simultaneously.

12. The method of claim 1 wherein said effective amount is from 0.001 mg/kg of the subject to 100 mg/kg of the subject.

13. The method of claim 1 wherein said effective amount is from 0.2 mg/kg of the subject to 10 mg/kg of the subject.

2. The method of 1, wherein the beta-glucan encapsulated in a liposome is admixed with an transmucosally acceptable carrier.